1. Home
  2. GLMD vs PCSA Comparison

GLMD vs PCSA Comparison

Compare GLMD & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLMD
  • PCSA
  • Stock Information
  • Founded
  • GLMD 2000
  • PCSA 2011
  • Country
  • GLMD Israel
  • PCSA United States
  • Employees
  • GLMD N/A
  • PCSA N/A
  • Industry
  • GLMD Biotechnology: Pharmaceutical Preparations
  • PCSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • GLMD Health Care
  • PCSA Health Care
  • Exchange
  • GLMD Nasdaq
  • PCSA Nasdaq
  • Market Cap
  • GLMD 4.6M
  • PCSA 4.3M
  • IPO Year
  • GLMD 2014
  • PCSA N/A
  • Fundamental
  • Price
  • GLMD $3.03
  • PCSA $0.84
  • Analyst Decision
  • GLMD
  • PCSA Strong Buy
  • Analyst Count
  • GLMD 0
  • PCSA 2
  • Target Price
  • GLMD N/A
  • PCSA $5.00
  • AVG Volume (30 Days)
  • GLMD 47.4K
  • PCSA 938.6K
  • Earning Date
  • GLMD 01-03-2025
  • PCSA 10-30-2024
  • Dividend Yield
  • GLMD N/A
  • PCSA N/A
  • EPS Growth
  • GLMD N/A
  • PCSA N/A
  • EPS
  • GLMD N/A
  • PCSA N/A
  • Revenue
  • GLMD N/A
  • PCSA N/A
  • Revenue This Year
  • GLMD N/A
  • PCSA N/A
  • Revenue Next Year
  • GLMD N/A
  • PCSA N/A
  • P/E Ratio
  • GLMD N/A
  • PCSA N/A
  • Revenue Growth
  • GLMD N/A
  • PCSA N/A
  • 52 Week Low
  • GLMD $2.56
  • PCSA $0.81
  • 52 Week High
  • GLMD $23.80
  • PCSA $9.28
  • Technical
  • Relative Strength Index (RSI)
  • GLMD 49.41
  • PCSA 34.98
  • Support Level
  • GLMD $2.81
  • PCSA $1.13
  • Resistance Level
  • GLMD $3.35
  • PCSA $0.99
  • Average True Range (ATR)
  • GLMD 0.27
  • PCSA 0.14
  • MACD
  • GLMD 0.06
  • PCSA -0.03
  • Stochastic Oscillator
  • GLMD 56.63
  • PCSA 3.66

About GLMD Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Share on Social Networks: